Selective Histone Deacetylase Inhibitors with Anticancer Activity

被引：50

作者：

Ma, Nan ^{[1
,2
,3
]}

Luo, Ying ^{[4
]}

Wang, Ying ^{[2
]}

Liao, Chenzhong ^{[4
]}

Ye, Wen-Cai ^{[2
,3
]}

Jiang, Sheng ^{[1
]}

机构：

[1] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Lab Med Chem, Guangzhou 510530, Guangdong, Peoples R China

[2] Jinan Univ, Coll Pharm, Inst Tradit Chinese Med & Nat Prod, Guangzhou 510632, Guangdong, Peoples R China

[3] China Pharmaceut Univ, Dept Nat Med Chem, Nanjing 210009, Jiangsu, Peoples R China

[4] Hefei Univ Technol, Sch Med Engn, Hefei 230009, Anhui, Peoples R China

来源：

CURRENT TOPICS IN MEDICINAL CHEMISTRY | 2016年 / 16卷 / 04期

关键词：

Class I; Class II; Class III; HDAC; HDAC1; HDAC6; Selective histone deacetylase inhibitors; BIOLOGICAL EVALUATION; CLASS-I; CLICK CHEMISTRY; CYCLIC TETRAPEPTIDES; HDAC INHIBITORS; LARGAZOLE ANALOGS; TRICHOSTATIN-A; HIGHLY POTENT; CANCER-CELLS; DESIGN;

D O I：

10.2174/1568026615666150813145629

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

HDAC inhibitors (HDACIs), which can be used to kill cancer cells through inhibiting histone deacetylase activity or altering the structure of chromatin, have emerged as efficacious agents in the treatment of cancer. With SAHA, FK228, belinostat and panobinostat approved by the FDA, displaying satisfying activity in both haematological and solid tumors of various tissues, efforts to create selective HDACIs have been attracted attention over the past several years. Herein, we mainly review the progress of selective HDAC inhibitors including class-selective and isoform-selective HDAC inhibitors.

引用

页码：415 / 426

页数：12

共 50 条

[31] Ligand based pharmacophore modelling of anticancer histone deacetylase inhibitors
Noureen, Nighat
Kalsoom, Saima
Rashid, Hamid
AFRICAN JOURNAL OF BIOTECHNOLOGY, 2010, 9 (25): : 3923 - 3931
[32] The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy?
Taddei, A
Roche, D
Bickmore, WA
Almouzni, G
EMBO REPORTS, 2005, 6 (06) : 520 - 524
[33] Rational development of histone deacetylase inhibitors as anticancer agents: A review
Acharya, MR
Sparreboom, A
Venitz, J
Figg, WD
MOLECULAR PHARMACOLOGY, 2005, 68 (04) : 917 - 932
[34] The clinical development of histone deacetylase inhibitors as targeted anticancer drugs
Marks, Paul A.
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (09) : 1049 - 1066
[35] Histone deacetylase inhibitors: Understanding a new wave of anticancer agents
Villar-Garea, A
Esteller, M
INTERNATIONAL JOURNAL OF CANCER, 2004, 112 (02) : 171 - 178
[36] Computational Studies on the Histone Deacetylases and the Design of Selective Histone Deacetylase Inhibitors
Wang, Difei
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2009, 9 (03) : 241 - 256
[37] Largazole Analogues as Histone Deacetylase Inhibitors and Anticancer Agents: An Overview of Structure-Activity Relationships
Poli, Giulio
Di Fabio, Romano
Ferrante, Luca
Summa, Vincenzo
Botta, Maurizio
CHEMMEDCHEM, 2017, 12 (23) : 1917 - 1926
[38] The activity of antiepileptic drugs as histone deacetylase inhibitors
Eyal, S
Yagen, B
Sobol, E
Altschuler, Y
Shmuel, M
Bialer, M
EPILEPSIA, 2004, 45 (07) : 737 - 744
[39] Bispyridinium dienes:: Histone deacetylase inhibitors with selective activities
Perez-Balado, Carlos
Nebbioso, Angela
Rodriguez-Grana, Paula
Minichiello, Annunziata
Miceli, Marco
Altucci, Lucia
de Lera, Angel R.
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (10) : 2497 - 2505
[40] A series of novel, potent, and selective histone deacetylase inhibitors
Jones, Philip
Altamura, Sergio
Chakravarty, Prasun K.
Cecchetti, Ottavia
De Francesco, Raffaele
Gallinari, Paola
Ingenito, Raffaele
Meinke, Peter T.
Petrocchi, Alessia
Rowley, Michael
Scarpelli, Rita
Serafini, Sergio
Steinkuhler, Christian
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (23) : 5948 - 5952

← 1 2 3 4 5 →